Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Moexipril/hydrochlorothiazide Generic Name & Formulations
Legal Class
Rx
General Description
Moexipril HCl, hydrochlorothiazide; 7.5mg/12.5mg, 15mg/12.5mg, 15mg/25mg; scored tabs.
Pharmacological Class
ACE inhibitor + diuretic.
How Supplied
Contact supplier
Manufacturer
Moexipril/hydrochlorothiazide Indications
Indications
Hypertension (not for initial therapy).
Moexipril/hydrochlorothiazide Dosage and Administration
Adult
Take 1 hour before a meal. Switching from monotherapy with either component: 1 tab once daily, then adjust; usual max 30mg/50mg per day. Allow 2–3 weeks for titration of HCTZ component. Or, substitute for individually-titrated components.
Children
Not established.
Moexipril/hydrochlorothiazide Contraindications
Contraindications
History of ACEI-associated angioedema. Anuria. Sulfonamide allergy. Concomitant aliskiren in patients with diabetes.
Moexipril/hydrochlorothiazide Boxed Warnings
Boxed Warning
Fetal toxicity.
Moexipril/hydrochlorothiazide Warnings/Precautions
Warnings/Precautions
Fetal toxicity may develop; discontinue if pregnancy is detected. Renal impairment (CrCl ≤40mL/min): not recommended. Discontinue if angioedema, laryngeal edema, jaundice, or marked elevation of hepatic enzymes occurs. Renal or hepatic dysfunction. Salt/volume depletion. CHF. Ischemic heart disease. Aortic or renal artery stenosis. Cerebrovascular disease. Dialysis (esp. high-flux membrane). Surgery. Diabetes. Gout. Asthma. Postsympathectomy. Monitor WBC counts in renal or collagen vascular disease. SLE. Acute myopia and secondary angle-closure glaucoma. Monitor electrolytes and renal function. Elderly. Neonates. Pregnancy (Cat.D); monitor. Nursing mothers: not recommended.
Moexipril/hydrochlorothiazide Pharmacokinetics
See Literature
Moexipril/hydrochlorothiazide Interactions
Interactions
See Contraindications. Dual inhibition of the renin-angiotensin system with ARBs, ACEIs, or aliskiren may increase risk of hypotension, hyperkalemia, renal function changes; monitor closely. Concomitant aliskiren in renal impairment (CrCl <60mL/min): not recommended. May cause hyperkalemia with K+ sparing diuretics, K+ supplements, or K+ containing salt substitutes. Hypokalemia with corticosteroids, ACTH, amphotericin B. May increase lithium, digitalis, diazoxide toxicity. Alcohol, CNS depressants may increase orthostatic hypotension. Adjust antidiabetic, antigout medications. Potentiates nondepolarizing muscle relaxants. Antagonizes norepinephrine. May be antagonized by, and renal toxicity potentiated by NSAIDs (including COX-2 inhibitors): monitor renal function in elderly and/or volume-depleted. May interfere with parathyroid tests. Reduced absorption with cholestyramine and colestipol resins. Nitritoid reactions with concomitant injectable gold (eg, sodium aurothiomalate); rare.
Moexipril/hydrochlorothiazide Adverse Reactions
Adverse Reactions
Cough, dizziness, fatigue, headache, hyperuricemia, electrolyte disturbances, hyperglycemia, rash, facial flushing, GI upset, angioedema (eg, intestinal), orthostatic hypotension, neutropenia; rare: hepatic failure.
Moexipril/hydrochlorothiazide Clinical Trials
See Literature
Moexipril/hydrochlorothiazide Note
Notes
Formerly known under the brand name Uniretic.
Moexipril/hydrochlorothiazide Patient Counseling
See Literature
